CCL22 and neoplasm: Interestingly, DC_LAMP3 cells were predicted to deliver both attracting (CCL19-CCR7/CXCR3 and CCL17/CCL22-CCR4) and activating (CD70-CD27/TNFRSF17 and IL15-IL2RB/IL2RG) signals to lymphocytes, but on the other hand, DC_LAMP3 inhibited anti-tumor T cell activity through a high expression of CD274 (PD-L1).